One Biosciences, founded by Dr. Céline Vallot, Curie Institute and Home Biosciences in 2020, is an AI driven single cell transcriptomic oncology solutions company that is pioneering clinical grade single-cell tumor transcriptomic profiling. They aim to help clinicians select optimal treatments for their patients by decoding tumor heterogeneity from standard clinical samples, while enabling pharmaceutical companies to improve clinical trial outcomes.
One Biosciences benefited from the MATWIN acceleration programme in 2024-25, and in May 2025 was awarded ‘Best Innovation – Precision Medicine/Diagnostics category’ by the prestigious MATWIN International Board.
One Biosciences Announces €15 Million Series A Financing led by major investors. This funding accelerate the development and the clinical validation of OneMap™, a proprietary artificial intelligence (AI) driven single cell transcriptomic oncology platform. It provides clinicians with tumor information from routine tumor biopsy samples, enabling therapeutic decisions based on analysis data in just 2 weeks. OneMap™ will be validated through real-world studies, and compared with existing solutions in several indications in Europe and the USA.
The funding will also support the establishment of strategic partnerships with pharmaceutical and biotech companies looking to integrate OneCure™, One Biosciences’ proprietary single-cell offering, into their drug development programs and clinical trials.
Read the full press release : https://onebiosciences.fr/content/uploads/2025/07/PR-One-Biosciences-series-A.pdf
